Search Results - "Erdkamp, Frans L.G"

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer by Tol, Jolien, Koopman, Miriam, Cats, Annemieke, Rodenburg, Cees J, Creemers, Geert J.M, Schrama, Jolanda G, Erdkamp, Frans L.G, Vos, Allert H, van Groeningen, Cees J, Sinnige, Harm A.M, Richel, Dirk J, Voest, Emile E, Dijkstra, Jeroen R, Vink-Börger, Marianne E, Antonini, Ninja F, Mol, Linda, van Krieken, Johan H.J.M, Dalesio, Otilia, Punt, Cornelis J.A

“…Capecitabine, oxaliplatin, and bevacizumab are standard treatment for metastatic colorectal cancer. This trial tested whether adding cetuximab to this…”
Get full text

Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial by Hamberg, Paul, Bos, Monique M.E.M, Braun, Hans J.J, Stouthard, Jacqueline M.L, van Deijk, Gert A, Erdkamp, Frans L.G, van der Stelt-Frissen, Iris N, Bontenbal, Marijke, Creemers, Geert-Jan M, Portielje, Johanneke E.A, Pruijt, Johannes F.M, Loosveld, Olaf J.L, Smit, Willem M, Muller, Erik W, Schmitz, Paul I.M, Seynaeve, Caroline, Klijn, Jan G.M

“…Abstract Background Because chemotherapy for metastatic breast cancer (MBC) is associated with relevant toxicity, sequential monotherapy trastuzumab followed…”
Get full text

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group by Simkens, Lieke H J, MD, van Tinteren, Harm, PhD, May, Anne, PhD, ten Tije, Albert J, MD, Creemers, Geert-Jan M, MD, Loosveld, Olaf J L, MD, de Jongh, Felix E, MD, Erdkamp, Frans L G, MD, Erjavec, Zoran, MD, van der Torren, Adelheid M E, MD, Tol, Jolien, MD, Braun, Hans J J, MD, Nieboer, Peter, MD, van der Hoeven, Jacobus J M, Prof, Haasjes, Janny G, MD, Jansen, Rob L H, MD, Wals, Jaap, MD, Cats, Annemieke, MD, Derleyn, Veerle A, MD, Honkoop, Aafke H, MD, Mol, Linda, MSc, Punt, Cornelis J A, Prof, Koopman, Miriam, Dr

“…Summary Background The optimum duration of first-line treatment with chemotherapy in combination with bevacizumab in patients with metastatic colorectal cancer…”
Get full text

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial by Tjan-Heijnen, Vivianne C G, van Hellemond, Irene E G, Peer, Petronella G M, Swinkels, Astrid C P, Smorenburg, Carolien H, van der Sangen, Maurice J C, Kroep, Judith R, De Graaf, Hiltje, Honkoop, Aafke H, Erdkamp, Frans L G, van den Berkmortel, Franchette W P J, de Boer, Maaike, de Roos, Wilfred K, Linn, Sabine C, Imholz, Alexander L T, Seynaeve, Caroline M, Kitzen, J.J.E.M., Strobbe, L.J.A., Kouwenhoven, E.A., van Dalen, T., van Overbeeke, A.J., Nuytinck, J.K.S., Arntz, I.E., Blaisse, R.J.B., Stockmann, H.B.A.C., Nijhuis, P.H.A., Veldhuis, G.J., Mastboom, W.J.B., van Riel, J.M.G.H., van Dam, J.H., den Boer, M.O., Agterof, M.J., de Roos, M.A.J., Roumen, R.M.H., van der Hoeven, J.J.M., Beeker, A., Koelemij, R., van Bochove, A., Madretsma, G.S., Siemerink, E.J.M., Guicherit, O.R., Vos, A.H., Nieuwenhuijzen, G.A.P., Kehrer, D.F.S., Valster, F.A.A., Tanis, B.C., van Voorthuizen, T., van der Velden, A.M.T., Hellingman, R.A., Vree, R., van Rossum-Schornagel, Q., Meerum Terwogt, J.M., van Leeuwen-Breuk, W.G., Haasjes, J.G., Davidis-van Schoonhoven, M.A., Vriens, E.J.C., Jagers, M., Muller, E.W., Schiphorst, P.P.J.B.M., van Groeningen, C.J., van Dijk, M.A., Janssens- van Vliet, E., Schepers, E.E.M., Merkus, J.W.S., van Diemen, N.G.J., van Doorn, R.C., Bosscha, K., den Toom, R., van der Velden, P.C., van Rossum, C.T.A.M., Oosterkamp, H.M., van Hillegersberg, R., Jas, B., Weernink, E.E.M., Ketel, J.M.A., Jansen, J.J., Maring, J.K., Govaert, M.J.P.M., Kamm, Y.J.L., Vleugel, M.M., Hovenga, S., de Boer, J., Potthoff, H., Sommeijer, D.W., van Dulken, E.J.

“…The effect of extended adjuvant aromatase inhibition in hormone receptor-positive breast cancer after sequential endocrine therapy of tamoxifen followed by an…”
Get full text

The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice by Claessens, Anouk K.M., Ibragimova, Khava I.E., Geurts, Sandra M.E., Bos, Monique E.M.M., Erdkamp, Frans L.G., Tjan-Heijnen, Vivianne C.G.

“…•Single-agent chemotherapy should be preferred to combination chemotherapy.•Longer chemotherapy durations do not adversely impact QoL within clinical…”
Get full text

Effects of an Exercise Program in Colon Cancer Patients undergoing Chemotherapy by VAN VULPEN, JONNA K, VELTHUIS, MIRANDA J, STEINS BISSCHOP, CHARLOTTE N, TRAVIER, NOÉMIE, VAN DEN BUIJS, BRAM J W, BACKX, FRANK J G, LOS, MAARTJE, ERDKAMP, FRANS L G, BLOEMENDAL, HAIKO J, KOOPMAN, MIRIAM, DE ROOS, MARNIX A J, VERHAAR, MARLIES J, TEN BOKKEL-HUININK, DAAN, VAN DER WALL, ELSKEN, PEETERS, PETRA H M, MAY, ANNE M

“…PURPOSEFatigue is a common problem among colon cancer patients and typically increases during chemotherapy. Exercise during chemotherapy might have beneficial…”
Get full text

Four-year effects of exercise on fatigue and physical activity in patients with cancer by Witlox, Lenja, Hiensch, Anouk E, Velthuis, Miranda J, Steins Bisschop, Charlotte N, Los, Maartje, Erdkamp, Frans L G, Bloemendal, Haiko J, Verhaar, Marlies, Ten Bokkel Huinink, Daan, van der Wall, Elsken, Peeters, Petra H M, May, Anne M

“…In the earlier randomized controlled Physical Activity during Cancer Treatment (PACT) study, we found beneficial effects of an 18-week supervised exercise…”
Get full text

Trajectories of health-related quality of life and psychological distress in patients with colorectal cancer: A population-based study by Qaderi, Seyed M., van der Heijden, Joost A.G., Verhoeven, Rob H.A., de Wilt, Johannes H.W., Custers, Jose A.E., Beets, Geerard L., Belt, Eric J.Th, Berbée, Maaike, Beverdam, Frederique H., Blankenburgh, Ruud, Coene, Peter Paul L.O., de Groot, Jan Willem B., de Hingh, Ignace H.J.T., de Vos, Aad I., de Wilt, Johannes H.W., Dekker, Jan Willem T., Erdkamp, Frans L.G., Haringhuizen, Annebeth W., Helgason, Helgi H., Hendriks, Mathijs P., Hoekstra, Ronald, Ijzermans, Jan N.M., Jansen, Jan, Kloppenberg, Frank W.H., Los, Maartje, Meijerink, Martijn R., Mekenkamp, Leonie J.M., Nieboer, Peter, Peeters, Koen C.M.J., Peters, Natascha A.J.B., Polée, Marco B., Pruijt, Johannes F.M., van Ufford-Mannesse, Patricia Quarles, Rietbroek, Ron C., Schiphorst, Anandi H.W., van der Velden, Arjan Schouten, Schrauwen, Ruud W.M., Sie, Mark P.S., Simkens, Lieke, Sommeijer, Dirkje W., Sonneveld, Dirk J.A., Spierings, Leontine E.A., Stockmann, Hein B.A.C., Talsma, Koen, ten Tije, Albert J., Terheggen, Frederiek, Tjin-A-Ton, Manuel L.R., Valkenburg-van Iersel, Liselot B.J., van Cruijsen, Hester, Velden, Ankie M.T. van der, van Dodewaard-de Jong, Joyce M., van Lent, Anja U.G., van Voorthuizen, Theo, Vermaas, Maarten, Vles, Wouter J., Vogelaar, Jeroen F.J., Zimmerman, David D.E.

“…The aim of this nationwide cohort study was to examine the course of symptoms and trajectories of health-related quality of life (HR-QoL) and psychological…”
Get full text

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol by Zeverijn, Laurien J, Geurts, Birgit S, Battaglia, Thomas W, van Berge Henegouwen, Jade M, de Wit, Gijs F, Hoes, Louisa R, van der Wijngaart, Hanneke, van der Noort, Vincent, Roepman, Paul, de Leng, Wendy W J, Jansen, Anne M L, Chalabi, Myriam, van Herpen, Carla M L, Devriese, Lot A, Erdkamp, Frans L G, Labots, Mariette, de Jonge, Maja J A, Kerver, Emile D, Bins, Adriaan D, Leek, Lindsay V M, Notohardjo, Jessica C L, van den Eertwegh, Alfonsus J M, Wessels, Lodewyk F A, Verheul, Henk M W, Gelderblom, Hans, van de Haar, Joris, Voest, Emile E

“…The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable…”
Get full text

The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care by Derksen, Jeroen W. G., Vink, Geraldine R., Elferink, Marloes A. G., Roodhart, Jeanine M. L., Verkooijen, Helena M., van Grevenstein, Wilhelmina M. U., Siersema, Peter D., May, Anne M., Koopman, Miriam

“…Real-world data (RWD) sources are important to advance clinical oncology research and evaluate treatments in daily practice. Since 2013, the Prospective Dutch…”
Get full text

The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry by Meegdes, Marissa, Geurts, Sandra M. E., Erdkamp, Frans L. G., Dercksen, Marcus Wouter, Vriens, Birgit E. P. J., Aaldering, Kirsten N. A., Pepels, Manon J. A. E., Winkel, Linda M. H., Teeuwen, Nathalie J. A., Boer, Maaike, Tjan‐Heijnen, Vivianne C. G.

“…In August 2017, cyclin‐dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy have been reimbursed in the Netherlands for patients with…”
Get full text

The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry by Lammers, Senna W. M., Thurisch, Hannah, Vriens, Ingeborg J. H., Meegdes, Marissa, Engelen, Sanne M. E., Erdkamp, Frans L. G., Dercksen, M. Wouter, Vriens, Birgit E. P. J., Aaldering, Kirsten N. A., Pepels, Manon J. A. E., van de Winkel, Linda M. H., Peters, Natascha A. J. B., Tol, Jolien, Heijns, Joan B., van de Wouw, Agnes J., Teeuwen, Nathalie J. A., Geurts, Sandra M. E., Tjan-Heijnen, Vivianne C. G.

“…Purpose This study determines the prognostic impact of body mass index (BMI) in patients with hormone receptor-positive/human epidermal growth factor…”
Get full text

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry by Meegdes, Marissa, Ibragimova, Khava I. E., Lobbezoo, Dorien J. A., Vriens, Ingeborg J. H., Kooreman, Loes F. S., Erdkamp, Frans L. G., Dercksen, M. Wouter, Vriens, Birgit E. P. J., Aaldering, Kirsten N. A., Pepels, Manon J. A. E., van de Winkel, Linda M. H., Tol, Jolien, Heijns, Joan B., van de Wouw, Agnes J., Peters, Natascha A. J. B., Hochstenbach-Waelen, Ananda, Smidt, Marjolein L., Geurts, Sandra M. E., Tjan-Heijnen, Vivianne C. G.

“…Purpose The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the main parameters in guiding systemic treatment choices in breast…”
Get full text

Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer by Claessens, Anouk K M, Busschbach, Jan J V, Ramaekers, Bram L T, Erdkamp, Frans L G, Bouma, Jeanette M, van Leeuwen-Stok, A Elise, Tjan-Heijnen, Vivianne C G, Bos, Monique E M M

Get more information

Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer by Claessens, Anouk K M, Erdkamp, Frans L G, Lopez-Yurda, Marta, Bouma, Jeanette M, Rademaker-Lakhai, Jeany M, Honkoop, Aafke H, de Graaf, Hiltje, Tjan-Heijnen, Vivianne C G, Bos, Monique E M M

“…Previously, we showed that reintroduction of the same (first-line) chemotherapy at progression could only partially make up for the loss in efficacy as…”
Get more information

Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure by van Hellemond, Irene E G, Vriens, Ingeborg J H, Peer, Petronella G M, Swinkels, Astrid C P, Smorenburg, Carolien H, Seynaeve, Caroline M, van der Sangen, Maurice J C, Kroep, Judith R, de Graaf, Hiltje, Honkoop, Aafke H, Erdkamp, Frans L G, van den Berkmortel, Franchette W P J, Kitzen, Jos J E M, de Boer, Maaike, de Roos, Wïlfred K, Linn, Sabine C, Imholz, Alexander L T, Tjan-Heijnen, Vivianne C G

“…Aromatase inhibitors (AIs) are given as adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women, also to those with…”
Get full text

Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study by Hellemond, Irene E.G., Smorenburg, Carolien H., Peer, Petronella G.M., Swinkels, Astrid C.P., Seynaeve, Caroline M., Sangen, Maurice J.C., Kroep, Judith R., de Graaf, Hiltje, Honkoop, Aafke H., Erdkamp, Frans L.G., Berkmortel, Franchette W.P.J., Boer, Maaike, Roos, Wilfred K., Linn, Sabine C., Imholz, Alexander L.T., Tjan‐Heijnen, Vivianne C.G.

“…The phase III DATA study investigates the efficacy of adjuvant anastrozole (6 vs. 3 year) in postmenopausal women with breast cancer previously treated with…”
Get full text

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure by Hellemond, Irene E.G., Vriens, Ingeborg J.H., Peer, Petronella G.M., Swinkels, Astrid C.P., Smorenburg, Carolien H., Seynaeve, Caroline M., Sangen, Maurice J.C., Kroep, Judith R., Graaf, Hiltje, Honkoop, Aafke H., Erdkamp, Frans L.G., Berkmortel, Franchette W.P.J., Boer, Maaike, Roos, Wilfred K., Linn, Sabine C., Imholz, Alexander L.T., Tjan‐Heijnen, Vivianne C.G.

“…The DATA study (NCT00301457) compared 6 and 3 years of anastrozole in postmenopausal women with hormone receptor‐positive early breast cancer after 2–3 years…”
Get full text

The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer by Claessens, Anouk K. M., Timman, Reinier, Busschbach, Jan J., Bouma, Jeanette M., Rademaker-Lakhai, Jeany M., Erdkamp, Frans L. G., Tjan-Heijnen, Vivianne C. G., Bos, Monique E. M. M.

“…Background The Stop&Go study randomized patients with advanced breast cancer to intermittent (two times four) or continuous (eight subsequent cycles) first-…”
Get full text

Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG) by Claessens, Anouk K. M., Bos, Monique E. M. M., Lopez-Yurda, Marta, Bouma, Jeanette M., Rademaker-Lakhai, Jeany M., Honkoop, Aafke H., de Graaf, Hiltje, van Druten, Edith, van Warmerdam, Laurence J. C., van der Sangen, Maurice J. C., Tjan-Heijnen, Vivianne C. G., Erdkamp, Frans L. G.

“…Purpose We determined if intermittent first-line treatment with paclitaxel plus bevacizumab was not inferior to continuous treatment in patients with…”
Get full text